Introduction
Perrault syndrome (MIM #233400), the association of primary ovarian insufficiency and bilateral sensorineural hearing loss (SNHL), is an autosomal recessive disorder first described in 1951 by Perrault et al. (1951) . It is a rare disorder affecting both females and males. However, only females have gonadal dysgenesis or primary ovarian insufficiency in the context of a normal female karyotype (46,XX) (Newman et al., 1993 (Newman et al., -2017 . Azoospermia has been reported in one male with Perrault syndrome (Demain et al., 2016) . Male fertility is not assessed routinely in families with Perrault syndrome; thus, the male fertility phenotype, if there is one, remains unclear. The SNHL, present in both sexes, is bilateral and ranges in severity from progressive moderate with early-childhood onset to congenital profound. Neurological features described in some affected individuals include developmental delay or intellectual disability, cerebellar ataxia, and motor and sensory peripheral neuropathy. SNHL is the first clinical manifestation, although a formal diagnosis of Perrault syndrome may not be made until a failure of puberty (primary amenorrhea) or secondary amenorrhea is noted in affected young women (Newman et al., 1993 (Newman et al., -2017 ; SNHL is usually identified in a sibling of a known affected individual or increasingly through genetic testing of an individual with childhood hearing loss (Ahmed et al., 2015; Demain et al., 2016) . Biallelic pathogenic variants in five different genes have been identified in Perrault syndrome to date: HSD17B4 (MIM #233400) (Pierce et al., 2010) , HARS2 (MIM #614926) (Pierce et al., 2011) , CLPP (MIM #614129) (Jenkinson et al., 2013) , LARS2 (MIM #615300) (Pierce et al., 2013) , and C10orf2 (MIM #616138) (Morino et al., 2014) .
Here, we report on a Moroccan family with Perrault syndrome and marfanoid habitus because of a previously reported homozygous c.1565C > A p. 
Patients and methods

Case report
The proband was a 23-year-old woman who presented to the Genetics Department in Rabat with primary amenorrhea and hearing loss. She was the eldest child of five siblings. The parents were first cousins and both are healthy (Fig. 1a) . Because of speech delay, an audiogram was performed at 6 years of age. She was diagnosed with bilateral moderate to severe SNHL that presented as an uncommon audiometric configuration of low-frequency hearing loss. On examination at 23 years, she had a long face, thin fingers, and a high-arched palate. She had marfanoid body proportions, measuring 170 cm in height with a 180 cm arm span (ratio: 1.06, normal < 1.05) and a weight of 60 kg. The upper-to-lower body segment ratio was reduced at 0.81 (normal ratio: 0.89-0.95). Physical examination indicated that axillary hair was present, pubic hair was at stage 4, and breast development was bilaterally at Tanner stage 2. Neurological and systemic examinations were normal. Hormone studies were consistent with hypergonadotropic hypogonadism, with elevated levels of follicle stimulating hormone (51 mIU/ml, normal range: 1.24-7.8 mIU/ml), and luteinizing hormone (16.29 mIU/ml, normal range: 1.42-15.4 mIU/ml).
Her karyotype was 46,XX. Pelvic ultrasonography indicated a hypoplasic uterus and her ovaries could not be visualized.
Audiometric evidence was consistent with a unifying diagnosis of Perrault syndrome. She has now been fitted with a hearing aid that has improved her hearing, and is currently receiving estrogen-replacement therapy that led to the appearance of secondary sexual characteristics and a normal menstruation cycle.
The 16-year-old brother of the proband was diagnosed with bilateral moderate to severe SNHL and fitted with a hearing aid. He also had a long face and a high-arched palate. He had progressed to Tanner stage 5 of puberty, with a height and weight of 175 cm and 75 kg, respectively. His neurological examination was normal. The three additional female siblings were unaffected.
Blood samples from all the seven members of the family were collected after written informed consent was obtained in accordance with the Declaration of Helsinki protocols and approval of the local institutional review boards (NRES 16/WA/0017). DNA was isolated using standard techniques (Miller et al., 1988) . 
Whole-exome sequencing
Whole-exome sequencing was performed on the proband. The SureSelect Human All Exon V5 Panel (Agilent, Santa Clara, California, USA) was used for library preparation and sequencing was performed on the HiSeq 2500 (Illumina, San Diego, California, USA) as described previously (Smith et al., 2014) . The exome data were filtered for possible causative variants in the five genes associated with Perrault syndrome.
Sanger sequencing confirmation and segregation
The sequence variants were confirmed in the proband and available family members by Sanger sequencing using ABI big Dye v3.1 sequencing technology (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) (Fig. 1b) . Primer sequences are available on request.
Results
Whole-exome sequencing data analysis
A homozygous known pathogenic variant in LARS2, c.1565C > A p.(Thr522Asn) (NM_015340) (Pierce et al., 2013; Demain et al., 2016; www.ncbi.nlm.nih .gov/nuc core/NM_015340.3), was identified in the proband. No additional coding variants were identified in LARS2 or in any other Perrault syndrome genes.
Sanger sequencing confirmation and segregation
The variant segregated with the phenotype in that the affected brother was also homozygous for the variant, two unaffected sisters were heterozygous, and an unaffected sister was homozygous wild type.
Discussion
To date, eight variants have been identified in LARS2 in 11 individuals with Perrault syndrome (Table 1) . Here, we present, for the first time, a Moroccan family carrying a previously reported homozygous c.1565C > A; p. Thr522Asn variant in LARS2 (Pierce et al., 2013) . The variant in this family has been reported as a homozygous variant in two families and as a compound heterozygous variant in one family (Table 1) (Pierce et al., 2013; Demain et al., 2016) . Previously reported Moroccan families with Perrault syndrome had variants identified in HARS2 or C10orf2 (Lerat et al., 2016) .
LARS2 encodes a 903 amino-acid protein, mitochondrial leucyl-tRNA synthetase (mtLeuRS) (Bullard et al., 2000) . Aminoacyl-tRNA synthetases attach specific amino acids to the 3′ ends of their cognate tRNAs. Aminoacyl-tRNAsynthetase activity is required in the cytoplasm and mitochondria for the translation of nuclear and mitochondrial encoded genes, respectively. All except two aaRS, glycyl-tRNA synthetase and lysyl-tRNA synthetase, are encoded by separate genes for nuclear and mitochondrial functions (Diodato et al., 2014) . The human structure of mtLeuRS has not been elucidated. The variant residue, LeuRS (of Escherichia coli) p.Thr492 (analogous to human mtLeuRS p.Thr522), is located in the catalytic site and is in contact with several residues in the leucine-binding pocket (Pierce et al., 2013) . It has been suggested that substitution at this position might shift the position of the tRNA in the binding pocket, subsequently reducing aminoacylation efficiency (Pierce et al., 2013) . Recently, this variant has been shown to reduce the aminoacylation efficiency of human mtLeuRS nine-fold, although the mechanism of impairment is unknown (Riley et al., 2015) .
All individuals to date with Perrault syndrome because of the variant Thr522Asn, whether homozygous or compound heterozygous, have presented with SNHL, which is worse at low frequencies and can be progressive. The variability in the severity of hearing loss between families may be attributed to different genetic backgrounds. The low-frequency hearing loss appears to be a specific phenotype-genotype correlation linked to the variant Thr522Asn (Demain et al., 2016) . Our report supports the assertion by Demain et al. (2016) when they suggested that the variant LARS2 c.1565C > A (p.Thr522Asn) may be a hotspot and may be correlated to this unusual audiological pattern.
The ovarian dysfunction is variable in severity in Perrault syndrome and there seems to be no obvious genotype-phenotype correlations associated with any of the Perrault syndrome genes to date.
Although no individuals with Perrault syndrome because of variants in LARS2 have been reported to have neurological symptoms, all the patients were relatively young at genetic diagnosis. It is unclear whether neurological symptoms may develop later in life as part of a progressive aspect of the disease. Variants in LARS2 can be associated with a more severe phenotype. Compound heterozygous variants in LARS2, including p.Thr522Asn, were implicated in a severe multisystem phenotype in a baby. The variant in trans had a greater effect on catalytic activity than that shown for p.Thr522Asn (Riley et al., 2016) .
Marfanoid habitus has been noted previously in some individuals with Perrault syndrome, but this is the first genetically resolved case. Two previously reported unrelated individuals with Perrault syndrome and marfanoid habitus have undergone genetic testing, but no causative variants were identified (Kim et al., 2013; Demain et al., 2016) . In most cases of Perrault syndrome with marfanoid habitus, no genetic testing has been performed (Jacob et al., 2007; Ameen and Pinninti, 2012; Geethalakshmi et al., 2015) . Arachnodactyly has been reported in one individual with Perrault syndrome because of variants in C10orf2 and it has also been reported in a genetically unresolved case of Perrault syndrome (Lerat et al., 2016) . High-arched palate has also been reported as a clinical feature in a number of cases of Perrault syndrome (Nishi et al., 1988) , which, alongside Table 1 Genotypes and phenotypes of individuals with Perrault syndrome because of variants in 
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Lerat et al. Degree of hearing loss Perrault syndrome and marfanoid habitus Zerkaoui et al. 203 arachnodactyly, may represent a more subtle form of the marfanoid habitus phenotype. However, the evidence to date indicates that although marfanoid habitus is definitely a clinical feature associated with Perrault syndrome, it is not associated with any specific diseasecausing gene or variant.
It is difficult to confidently assert genotype-phenotype correlations in Perrault syndrome because of the low numbers of characterized and reported individuals and the high level of phenotypic and genotypic heterogeneity. Several studies have suggested factors that could modulate mitochondrial translation or replication to explain the phenotypic heterogeneity (Jenkinson et al., 2012; Pierce et al., 2013; Lerat et al., 2016) .
Perrault syndrome cases have been reported in countries worldwide. However, it is underestimated because males without an affected sister will likely be diagnosed with nonsyndromic deafness. Further, the prevalence of this condition is likely to be higher in countries with high levels of consanguinity, including Morocco (15.25%) (Jaouad et al., 2009) .
Conclusion
Perrault syndrome is an under-ascertained, genetically complex condition with further disease-associated genes still to be elucidated. The clinical spectrum of the disease remains incomplete; as new cases of Perrault syndrome are reported, new phenotypic features become apparent. Consequently, phenotype-genotype correlations remain difficult to establish and more patients are required to better define these relationships. Here, we have described the clinical and genetic data of a consanguineous Moroccan family with Perrault Syndrome carrying the previously reported mutation c.1565C > A; p.Thr522Asn. This diagnosis allowed us to provide appropriate management to the patients and to provide more accurate genetic counseling to this family.
